This article is more than 5 years old. Information may no longer be current.
APBI, WBI for early-stage breast cancer associated with similar 10-year outcomes
Click Here to Manage Email Alerts
Patients with early-stage breast cancer who underwent accelerated partial breast irradiation experienced comparable 10-year locoregional recurrence, distant metastasis and survival rates as those who underwent whole breast irradiation, according to study results presented at the Breast Cancer Symposium.
Researchers evaluated 3,009 patients with early-stage breast cancer who underwent breast-conserving therapy between 1980 and 2012. Of them, 2,528 underwent whole breast irradiation (WBI) and 481 underwent accelerated partial breast irradiation (APBI) through interstitial catheter or balloon-based brachytherapy.
Mean follow-up was 8.1 years for patients who underwent WBI and 7.8 years for patients who underwent APBI (P<.001).
Patients in the WBI group were more likely to have larger tumors (13 mm vs. 11.4 mm; P=.06). No differences in age (P=.88), tumor stage (P=1.0) or estrogen receptor status (P=1.0) existed between groups.
At follow-up, researchers reported a 4% rate of ipsilateral breast tumor recurrence in each arm (P=.11), as well as a 1% rate of regional recurrence in each arm (P=.20).
Researchers observed no significant differences in the rates of distant metastases (3% for WBI vs. 6% for APBI; P=.47) or contralateral breast failure (9% for WBI vs. 3% for APBI; P=.06).
DFS rates were comparable (93% for WBI vs. 91% for APBI; P=.10), as were 10-year rates of cause-specific survival (94% vs. 93%; P=.72) and OS (83% vs. 75%; P=.34).
Disclosure: The researchers report no relevant financial disclosures.
For more information:
Wobb J. Abstract #55. Presented at: Breast Cancer Symposium; Sept. 7-9, 2013; San Francisco.